Published in Clin Breast Cancer on February 01, 2003
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A (2011) 1.60
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 1.51
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol (2008) 1.25
Breast tumour angiogenesis. Breast Cancer Res (2007) 1.22
Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer (2004) 1.15
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene (2014) 1.10
Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia (2011) 1.02
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat (2016) 0.88
Update on molecular diagnostic tests in head and neck cancer. Semin Oncol (2008) 0.84
New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther (2010) 0.83
Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice? Int J Biochem Cell Biol (2007) 0.82
The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer. Mol Cancer Ther (2014) 0.82
Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol (2014) 0.81
Tissue Stiffness and Hypoxia Modulate the Integrin-Linked Kinase ILK to Control Breast Cancer Stem-like Cells. Cancer Res (2016) 0.79
The inefficacy of antiangiogenic therapies. J Angiogenes Res (2010) 0.78
The reality in the surveillance of breast cancer survivors-results of a patient survey. Breast Cancer (Auckl) (2008) 0.78
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer. Breast Cancer (Dove Med Press) (2013) 0.77
A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. PLoS One (2016) 0.75
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer. Breast Cancer (Dove Med Press) (2010) 0.75